Gufic Biosciences Limited (GBL) is a prominent global pharmaceutical company offering a wide spectrum of pharmaceutical products and services. Backed by a strong distribution network, the Company caters to both domestic and international markets and is consistently ranked among the Top 100 pharmaceutical companies in India.
Founded in July 1984, Gufic has built a niche in lyophilized injections, emerging as one of India’s leading and among the world’s largest manufacturers in this category. Its state-of-the-art, fully automated lyophilization facility in Navsari, Gujarat, and the recently commissioned Indore manufacturing plant, have significantly strengthened its production capabilities. Gufic’s lyophilized portfolio spans critical therapeutic areas including antibiotics, antifungals, cardiac care, infertility, antivirals, and proton pump inhibitors (PPIs).
The Company entered the listed space through a reverse merger with Central Finance, acquired by the promoters at around ₹40–42 per share. Post-merger, Gufic Biosciences Limited became listed on the BSE. Currently, GBL is engaged in the manufacturing and marketing of APIs, generic formulations, and related pharmaceutical services.
The promoters — the Choksi and Gandhi families — have a rich legacy in the Indian pharmaceutical industry. Their journey dates back to 1960 with the establishment of Lyka Labs. After parting ways in 1976, the Choksi family took over the manufacturing operations, leading to the formation of the Gufic group. Initially known as Gujarat Fine Chemicals, the Company started with bulk drug manufacturing and eventually expanded into formulations. Today, Gufic’s diversified portfolio covers ethical pharmaceuticals, herbal products, consumer products, and bulk drugs, marketed across domestic and global regions.
Over the years, Gufic has developed several successful brands that have achieved leadership positions in their respective categories, such as Shapers (sanitary napkins), Onergy, and Stretchnil. In 2000, the Company issued bonus shares in a 5:2 ratio.
Gufic has strategically divested certain ethical pharma brands at attractive valuations and plans to enhance investments in R&D, while scaling its presence in herbal and consumer product segments, where it foresees strong long-term demand. The Company aims to leverage India’s traditional knowledge base to build a competitive edge in herbal solutions.
In recent years, Gufic has also strengthened its corporate structure. Gufic Lifesciences Pvt. Ltd. was amalgamated into the Company in FY21, effective May 21, 2021. To expand its global footprint, Gufic incorporated two subsidiaries — GUFIC UK Limited (March 15, 2022) and Gufic Ireland Limited (March 2, 2023).
For more details click on the link below.
Gufic BioScience Limited
